Abstract:Osteoarthritis (OA) is a painful and disabling disease that affects millions of people worldwide. Symptom-alleviating treatments exist, although none with long-term efficacy. Furthermore, there are currently no disease-modifying OA drugs (DMOADs) with demonstrated efficacy in OA patients, which is, in part, attributed to a lack of full understanding of the pathogenesis of OA. The inability to translate findings from basic research to clinical applications also highlights the deficiencies in the available OA models at simulating the clinically relevant pathologies and responses to treatments in humans. In this review, the current status in the development of DMOADs will be first presented, with special attention to those in Phase II-IV clinical trials. Next, current in vitro, ex vivo, and in vivo OA models are summarized and the respective advantages and disadvantages of each are highlighted. Of note, the development and application of microphysiological or tissue-on-a-chip systems for modeling OA in humans are presented and the issues that need to be addressed in the future are discussed. Microphysiological systems should be given serious consideration for their inclusion in the DMOAD development pipeline, both for their ability to predict drug safety and efficacy in human clinical trials at present, as well as for their potential to serve as a test platform for personalized medicine. Impact statement At present, no disease-modifying osteoarthritis (OA) drugs (DMOADs) have been approved for widespread clinical use by regulatory bodies. The failure of developing effective DMOADs is likely owing to multiple factors, not the least of which are the intrinsic differences between the intact human knee joint and the preclinical models. This work summarizes the current OA models for the development of DMOADs, discusses the advantages/disadvantages of each, and then proposes future model development to aid in the discovery of effective and personalized DMOADs. The review also highlights the microphysiological systems, which are emerging as a new platform for drug development.

Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs

Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage

Harnessing the multifunctionality of lipid-based drug delivery systems for the local treatment of osteoarthritis

Intra-Articular Drug Delivery for Osteoarthritis Treatment

Recombinant protein drugs-based intra articular drug delivery systems for osteoarthritis therapy

Targeted treatment for osteoarthritis: drugs and delivery system

Dehydroepiandrosterone and Experimental Osteoarthritis.

Advancing drug delivery to articular cartilage: From single to multiple strategies

A brief review of current treatment options for osteoarthritis including disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics

Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions

Cartilage-targeted drug nanocarriers for osteoarthritis therapy

Progress and Challenges of Topical Delivery Technologies Meditated Drug Therapy for Osteoarthritis

Current Models for Development of Disease-Modifying Osteoarthritis Drugs

Polymer particles for the intra-articular delivery of drugs to treat osteoarthritis

Controlled Stimulus-Responsive Delivery Systems for Osteoarthritis Treatment

Nanoparticle–Cartilage Interaction: Pathology-Based Intra-articular Drug Delivery for Osteoarthritis Therapy

Responsive Hydrogel-Based Drug Delivery Platform for Osteoarthritis Treatment

Harnessing exosomes as cutting-edge drug delivery systems for revolutionary osteoarthritis therapy

Current Research on Pharmacologic and Regenerative Therapies for Osteoarthritis

Multimodal approach to intraarticular drug delivery in knee osteoarthritis

Targeted and responsive biomaterials in osteoarthritis